Clinical trials: Immune Checkpoint Blockade
Gastric Cancer, Adenocarcinoma of the Gastroesophageal Junction
Perioperative Chemo and Pembrolizumab in Gastric Cancer
This is a non-randomized, multi-site, open-label trial of pembrolizumab and chemotherapy in subjects with gastric or gastroesophageal (GE) junction adenocarcinoma.
- Trial name
- NCT02918162
- Testing
- Pembrolizumab, Standard of care chemotherapy regimen
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- Gulam Manji
Cancer
Immune Checkpoint Blockade Therapy Using 18F-FLT PET/CT
In the current study, advanced positron emission tomography/computed tomography (PET/CT) and positron emission tomography/magnetic resonance (PET/MR) imaging methods will be used to validate the hypothesis that participants…
- Trial name
- NCT04271436
- Testing
- FDG PET/CT, FLT PET/CT, PET/MR
- Sponsor
- Washington University School of Medicine
Patient Reported Outcome Measures, Patient Safety
ePRO-based Model of Care to Manage and Monitoring Symptoms of Cancer Patients Treated With Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (IrAEs) throughout and beyond treatment duration. These IrAEs can be varied and difficult to predict, as they can involve almost any organ, regardless of…
- Trial name
- IePRO (NCT05530187)
- Testing
- Electronic Patient-reported Outcomes-based Model of Care
- Where
- 2 sites in Switzerland
- Volunteers
- 198 people
- Sponsor
- Manuela Eicher
Esophageal Adenocarcinoma
RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus
A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal adenocarcinoma and to evaluate…
- Trial name
- RICE (NCT04159974)
- Testing
- Durvalumab 50 MG/ML, Tremelimumab
- Where
- 2 sites in Germany
- Volunteers
- 56 people
- Sponsor
- University of Cologne
Pancreatic Neoplasms, Pancreatic Cancer
Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer
Background: Stereotactic body radiation therapy (SBRT) is used to treat cancer. It is a way of giving very focused beams of radiation to tumors.
- Conditions
- Pancreatic Neoplasms, Pancreatic Cancer, Cancer of Pancreas, Cancer of the Pancreas
- Trial name
- NCT02311361
- Testing
- Durvalumab, Tremelimumab, Sterostatic body radiation therapy (SBRT)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Mesothelioma
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
The proposed study will evaluate the safety and feasibility of neoadjuvant nivolumab +/- ipilimumab in resectable MPM. In addition, maintenance nivolumab will be administered for 1 year following completion of standard…
- Trial name
- NCT03918252
- Testing
- Nivolumab Injection, Ipilimumab Injection
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Melanoma, Immune Defect
Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma
Cutaneous melanoma is a bad prognosis skin cancer, which can be treated with immune checkpoint inhibitors (ICI), such as anti-PD-1 (nivolumab, nivo) and anti-CTLA-4 (ipilimumab, ipi).
- Conditions
- Melanoma, Immune Defect, Tumor Skin
- Trial name
- ATPIC (NCT05867004)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Institut Claudius Regaud
Colorectal Cancer
Histidine and Immunotherapy Response in Colorectal Cancer
This observational study aims to investigate the role of histidine and its transporter SLC15A3 in modulating the sensitivity of colorectal cancer to immunotherapy.
- Trial name
- NCT07586293
- Testing
- Immunohistochemistry or immunofluorescence, Serum metabolomic analysis or ELISA, Flow cytometry
- Volunteers
- 150 people
- Sponsor
- Jing-yuan Fang, MD, Ph. D
Melanoma
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
To Determine the feasibility, compliance and adherence to PreFED intervention in resectable melanoma patients initiating neoadjuvant Ipi/Nivo.
- Trial name
- NCT06548789
- Testing
- Prebiotic Xnack Packouts
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma
LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma
A Phase 2 study to investigate the efficacy and safety of lerapolturev alone or in combination with a programmed death receptor-1 (anti-PD-1) inhibitor.
- Trial name
- NCT04577807
- Testing
- Lerapolturev, Anti-PD-1 Checkpoint Inhibitor
- Where
- 12 sites in United States
- Volunteers
- 27 people
- Sponsor
- Istari Oncology, Inc.
Invasive Fungal Infections
ImPACt on Invasive Fungal Infections by Immune Checkpoint Inhibition
This observational study aims to compare immune checkpoint expression in blood samples from patients with invasive fungal infections (IFI) against healthy controls.
- Trial name
- PACIFIC (NCT04533087)
- Testing
- No intervention
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University of Cologne
Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung
BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer
BIOLUMA is a multicentric non-randomised phase II trial in patients with non-squamous non-small cell lung cancer (NSCLC) (Cohort 1) and patients with small-cell lung cancer (SCLC) (Cohort 2) after failure of platinum-based…
- Trial name
- NCT03083691
- Testing
- Nivolumab, Ipilimumab
- Where
- 16 sites in Germany
- Volunteers
- 90 people
- Sponsor
- Lung Cancer Group Cologne
Non Small Cell Lung Cancer
Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiota Transplant in Advanced Non-Small Cell Lung Cancer
This study is being done to answer the following question: Can adding a treatment called Fecal Microbiota Transplant (FMT) to the usual treatment delay the growth or spread of cancer better than the usual treatment alone? FMT…
- Trial name
- LUNA-2 (NCT07890493)
- Testing
- LND101, Carboplatin, Pemetrexed
- Volunteers
- 160 people
- Sponsor
- Canadian Cancer Trials Group
Pancreatic Ductal Adenocarcinoma
Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma
The purpose of this study is to combine standard radiation therapy with drugs that encourages the body's immune system against cancer cells and simultaneously adding drugs which also target the pathway that the tumor uses to…
- Trial name
- AIRPanc (NCT06048484)
- Testing
- Stereotactic body radiotherapy (SBRT), Zimberelimab, Quemliclustat
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Gulam Manji
Cancer
Study to Determine if the Flu Vaccine Increases the Risk of Muscle Damage in Participants Taking Drugs That Block Certain Proteins Made by Some Types of Immune System Cells
A retrospective, observational study conducted on cancer patients receiving a drug that blocks certain proteins made by some types of immune system cells
- Trial name
- NCT03644498
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 1,056 people
- Sponsor
- Bristol-Myers Squibb
Small-Cell Lung Cancer (SCLC)
A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer
This study will enroll patients with limited-stage small cell lung cancer (SCLC). Patients will receive chemotherapy (etoposide and platinum-based drugs) combined with dual immune checkpoint blockade (PD-1/CTLA-4) and thymosin…
- Trial name
- NCT07103408
- Testing
- Immuno-chemotherapy, Radiotherapy, Consolidative therapy
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Sun Yat-sen University
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
This phase II/III compares the standard therapy (chemotherapy plus cetuximab) versus adding bevacizumab to standard chemotherapy, versus combination of just bevacizumab and atezolizumab in treating patients with head and neck…
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT05063552
- Testing
- Atezolizumab, Bevacizumab, Biospecimen Collection
- Where
- 172 sites in United States
- Volunteers
- 430 people
- Sponsor
- National Cancer Institute (NCI)
Cutaneous Malignant Melanoma, Renal Cell Cancer
Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer
This is a pilot study of combination low dose rate brachytherapy (LDR) added to standard of care (SOC) immunotherapy in stage III and IV melanoma, stage IV renal call cancer, and stage IV urothelial cancer.
- Conditions
- Cutaneous Malignant Melanoma, Renal Cell Cancer, Urothelial Cancer of Renal Pelvis
- Trial name
- NCT04620603
- Testing
- Low Dose Rate Brachytherapy (LDR), Standard-of-Care Immunotherapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Case Comprehensive Cancer Center